Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835474 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL21835562 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EAPOBEC3AAPOBEC3GCYP1A2 | |
| SCHEMBL28612241 | 0.76 | MAOA (0.31) | — | |
| SCHEMBL15261543 | 0.75 | — | — | |
| SCHEMBL15273689 | 0.73 | CSNK2A1 (0.32) | — | |
| SCHEMBL15273651 | 0.71 | — | — | |
| SCHEMBL15260721 | 0.70 | — | — | |
| SCHEMBL22198893 | 0.70 | KDM4E (0.32) | KDM4E | |
| SCHEMBL15261311 | 0.69 | — | — | |
| SCHEMBL28612240 | 0.69 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033402-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| EP-3883573-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3856745-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | Dana Farber Cancer Institute, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020069118-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033402-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | ROS1, ALK, NTRK3 | SMN1; SMN2 1382/4885KDM4E 2318/4885APOBEC3A 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.